NASDAQ: CASI | 中文 | Contact Us

CASI News

CASI Hosts Nobel Laureate James P. Allison

September 10, 2019

CASI hosts a key opinion leader (KOL) symposium addressing innovations in cancer immunotherapy. A replay of Nobel Laureate James P. Allison Discussion on Immunotherapy Checkpoint Blockade in Cancer Therapy can be found at https://www.youtube.com/channel/UC5IBDAqhTqt5esL9r3dgQRQ.


Evomela Commercially Available In China

August 12, 2019

EVOMELA® received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. It is the only approved and commercially available melphalan product in China.

U.S. FDA-Approved Products In-Licensed for the Greater China Region

Evomela®

Multiple Myeloma

Zevalin®

Non-Hodgkin's Lymphoma

Marqibo®

Acute Lymphoblastic Leukemia

Pre-Clinical Candidates

CID-103

Multiple Myeloma

CNTC19

Hematological Malignancies
Learn more about our product pipeline

About Us

CASI Pharmaceuticals, Inc. is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company’s operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd. (“CASI China”), which is located in Beijing, China.

Learn More